Metabolic Research Peptides

Metabolic research peptides are the most active area in current incretin literature. The compounds in this category act on some combination of three receptors — GLP-1, GIP and glucagon — and the differences between them are differences of receptor coverage, not of potency alone. Tirzepatide engages GLP-1 and GIP. Retatrutide adds glucagon receptor agonism, which is what makes it a triple agonist and why it is studied separately rather than as a stronger version of the same thing.

That distinction matters when reading the literature. Preclinical and clinical findings for a dual agonist do not transfer to a triple agonist, and vice versa; the receptor pharmacology genuinely differs. Researchers comparing the two should treat them as separate compounds with separate evidence bases rather than points on a single scale.

All metabolic peptides in this category ship as lyophilised powder with a batch-matched Certificate of Analysis covering HPLC purity, mass spectrometry identity confirmation and LAL endotoxin assay. Retatrutide is stocked in 10mg, 20mg and 30mg vials, plus a bulk raw-material option priced per gram for larger research programmes.